HER-2 Expression in Pancreatic Duct Adenocarcinoma

Status Completed

Clinical Trial Summary

Pancreatic duct adenocarcinoma is a highly aggressive carcinoma that is associated with a poor prognosis. Detection of novel biological markers that are specifically over expressed in pancreatic duct adenocarcinoma and their subsequent targeting by anti cancer therapeutic modalities may improve patient's survival.

Clinical Trial Description

Pancreatic duct adenocarcinoma (PDAC) is a deadly neoplasm that showed current increase in its occurrence. There are many challenges in PDAC; the tumor is frequently associated with perineural invasion and angioinvasion, these lead to early metastasis.Another important challenge is that the tumor is associated with extensive fibrosis that prevents arrival of chemotherapeutic agents. Most modern anti-cancer therapeutic modalities depend on the biologic signature of the tumor. Human epidermal growth factor receptor-2 (HER-2) is a cell surface protein that is associated with enhanced cellular proliferation. HER-2 has been detected and successfully targeted in many human carcinomas as breast and gastric cancers. we aimed to evaluate the potential cancer-promoting effect of HER-2 in PDAC, in order to detect any possible benefits of its targeting by future therapeutic modalities. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06055647
Study type	Observational
Source	Sohag University
Contact
Status	Completed
Phase
Start date	January 1, 2017
Completion date	December 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05305001` - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Recruiting	`NCT05059444` - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Completed	`NCT01959672` - Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer	Phase 2
Recruiting	`NCT03673423` - Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer
Terminated	`NCT02495896` - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors	Phase 1
Recruiting	`NCT05351983` - Patient-derived Organoids Drug Screen in Pancreatic Cancer	N/A
Not yet recruiting	`NCT06026943` - Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer	N/A
Completed	`NCT03054987` - Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction	N/A
Terminated	`NCT02345460` - Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study	Phase 2
Recruiting	`NCT02072616` - Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.	Phase 3
Completed	`NCT02174887` - Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer	Phase 1
Recruiting	`NCT03703063` - Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer	Phase 1
Terminated	`NCT04077372` - Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers	N/A
Recruiting	`NCT03073785` - Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer	Phase 2
Completed	`NCT03665441` - Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC	Phase 3
Recruiting	`NCT04627246` - Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer	Phase 1
Not yet recruiting	`NCT06217666` - Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)	Phase 1
Recruiting	`NCT05585320` - A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT04119362` - PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer
Completed	`NCT03105921` - Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma	N/A